May. 15 AC Immune SA Announces Retirement of Andrea Pfeifer as CEO CI
May. 12 AC Immune CEO Andrea Pfeifer to Retire MT
May. 12 AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM AQ
May. 12 AC Immune SA Announces Executive Changes CI
Apr. 30 AC Immune: Q1 Earnings Snapshot AQ
Apr. 30 AC Immune First Quarter 2026 Financial and Corporate Updates AQ
Apr. 30 AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 30 AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease AQ
Apr. 30 AC Immune SA Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease CI
Apr. 07 AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly AQ
Apr. 07 AC Immune Extends Alzheimer's Drug Pact With Eli Lilly DJ
Apr. 07 AC Immune, Eli Lilly Amend Morphomer Tau License, Collaboration Agreement; Shares Up Pre-Bell MT
Apr. 07 AC Immune announces amendment to Morphomer® tau license and collaboration agreement with Lilly RE
Apr. 07 AC Immune SA and Eli Lilly Amend Tau Morphomer Collaboration Agreement CI
Mar. 19 AC Immune presents first in vivo images of brain TDP-43 pathology from Phase 1 trial of PET tracer ACI-19626, at AD/PDTM 2026 RE
Mar. 19 AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 AQ
Mar. 19 Ac Immune Sa Presents First in Vivo Images of Brain Tdp-43 Pathology from Phase 1 Trial of Pet Tracer Aci-19626 CI
Mar. 13 AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 13 AC Immune: Q4 Earnings Snapshot AQ
Mar. 13 AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update AQ
Mar. 06 AC Immune Announces Upcoming Industry Symposium on Parkinson's disease and Presentation at AD/PD 2026 AQ
Mar. 05 AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AQ
Feb. 24 AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor CI
Feb. 24 AC Immune initiates phase 1 clinical trial of NLRP3 inhibitor RE
Feb. 24 AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor AQ
No results for this search